Profile | GDS2987 / GI_5031706-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 12.5 | 41 |
GSM215244 | HMVEC_vehicle_rep2 | 29.2 | 57 |
GSM215253 | HMVEC_vehicle_rep3 | 31.1 | 64 |
GSM215254 | HMVEC_atorvastatin_rep1 | 81.4 | 74 |
GSM215282 | HMVEC_atorvastatin_rep3 | 100.7 | 76 |
GSM215344 | HMVEC_atorvastatin_rep2 | 53.4 | 69 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 24.9 | 44 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 21.4 | 40 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 35.4 | 50 |
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | 24.1 | 44 |
GSM215296 | HMVEC_SLx2119_rep3 | 13.7 | 23 |
GSM215297 | PASMC_vehicle_rep1 | 116.9 | 75 |
GSM215298 | PASMC_vehicle_rep2 | 119.1 | 75 |
GSM215310 | PASMC_vehicle_rep3 | 107.5 | 75 |
GSM215311 | PASMC_atorvastatin_rep1 | 87 | 73 |
GSM215312 | PASMC_atorvastatin_rep2 | 48.3 | 59 |
GSM215313 | PASMC_atorvastatin_rep3 | 88.9 | 72 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 156 | 78 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 84.9 | 72 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 131.4 | 77 |
GSM215327 | PASMC_SLx2119_rep1 | 67.3 | 69 |
GSM215328 | PASMC_SLx2119_rep2 | 60.4 | 67 |
GSM215329 | PASMC_SLx2119_rep3 | 76 | 72 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 17.1 | 43 |
GSM215332 | Fibroblasts_vehicle_rep3 | 21 | 54 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 9.7 | 26 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | 20.1 | 44 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 14.8 | 44 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 13.4 | 40 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 16.4 | 42 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 9.4 | 28 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 29.7 | 60 |
GSM215341 | Fibroblasts_SLx2119_rep3 |